MeAgain

What MeAgain does

MeAgain is a consumer mobile application purpose-built for individuals using GLP-1 medications such as Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, tirzepatide, and compounded versions. Founded in 2025 and operated by Dots Future Technologies, Inc. from 1460 Broadway, New York, the app consolidates medication timing (shots/pills), injection site rotation, food logging (photo, barcode, voice, search, quick-add), automatic protein/fiber/water calculation, side effect journaling with severity scoring, weight trends, and progress photos into a single iOS and Android experience. Notable technical components include the proprietary GLP-1 Plotter that estimates medication-level curves between doses, the Capy AI companion chatbot, computer-vision-based food photo recognition, and Apple Health interoperability. The product is positioned as a daily self-care companion and explicitly not a clinical or medical device.

The business operates a product-led, freemium go-to-market: a free core tier with full basic tracking, plus a Premium subscription reported at $69.99 and a stack of Unlimited in-app tiers ranging from $14.99 to $119.99 for richer Capy chat, deeper food analytics, Journey Cards, and advanced photo tools. Distribution is global via Apple App Store and Google Play, with marketing anchored by a 275-article SEO content library, social presence on Instagram, TikTok, Reddit, and Facebook, and an ambassador program of verified users. The company reports 421,000+ trackers, a 4.8 average rating across 20,988+ App Store reviews, and a #39 Health & Fitness category ranking. No enterprise customers, partnerships, M&A, or material institutional funding rounds are disclosed in the source material beyond a Freestyle Capital listing dated 2026-01-01.

Leadership consists of a co-founder (Rodrigo) and a Nutrition Lead (Erin Seprish, RDN) with 6 years of disordered-eating nutrition therapy and 2 years of GLP-1 specialization, with the company operating at 1–10 employees. Other confirmed signals include LegitScript verification for pharmacy/health-adjacent compliance, incorporation in New York, and the absence of disclosed subsidiaries, parent entities, regulatory actions, or restructuring events.

Name

MeAgain

Legal name

Dots Future Technologies, Inc.

Website

https://meagain.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

MeAgain operates a consumer mobile app that consolidates GLP-1 medication tracking, food logging, side effects, weight, and progress photos for Ozempic, Wegovy, Zepbound, and Mounjaro users via a freemium subscription model.

Ownership category

akta.pro rank

Product category

Consumer Health & Wellness App

akta.pro primary industry

Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)

akta.pro secondary industries

Wearables & Consumer IoT Integration Platforms (BYOD) (HLACAFAF), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)

Keywords

• GLP-1 medication tracking
• Weight loss app
• Medication companion
• Food logging software
• Health tracking app

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. MeAgain Premium Subscription: Freemium model with free core tracking features (shot/pill tracking, food logging, protein/fiber/water tracking, symptom logging, weight trends, progress photos) and premium subscription unlocking Capy AI companion, richer food data, Journey Cards, progress photo tools, and unlimited Capy chat. Subscription billed monthly, annually, or multi-year.
2. In-App Purchases: One-time in-app purchases for premium features and Unlimited access tiers at various price points ranging from $14.99 to $119.99.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

MeAgain sells a freemium mobile application (iOS and Android) that consolidates GLP-1 medication tracking (shots/pills, dose timing, injection site rotation), multi-method food logging (photo, barcode, voice, search, quick-add), automatic protein/fiber/water monitoring, side-effect journaling, weight trends, and progress photos in one daily-use companion. A Premium subscription unlocks Capy AI conversational support, richer analytics, Journey Cards, and unlimited chat, positioning MeAgain as a purpose-built daily companion for people on Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, tirzepatide, oral GLP-1s, and compounded versions.

Product overview

MeAgain is a single all-in-one GLP-1 tracker app designed for users of Ozempic, Wegovy, Zepbound, Mounjaro, and other GLP-1 medications. The core product consists of the MeAgain mobile app (available for iPhone and Android) which combines medication tracking (shots/pills, dose timing, injection sites), food logging (photo, barcode, voice, search, quick-add), nutrition monitoring (protein, fiber, water), side effect journaling, weight tracking, and progress photos. The app is offered as a free core version with a MeAgain Premium subscription unlocking enhanced AI companion (Capy), richer analytics, Journey Cards, and unlimited Capy chat. Key integrated features include the GLP-1 Plotter for medication-level estimation, Capy AI chatbot for conversational support, and Journey Cards for visual progress tracking. The product is built by Dots Future Technologies, Inc. and is positioned as a daily companion rather than a medical or clinical tool.

Differentiator

Problem solved

Functional benefit

Products and services

• MeAgain GLP-1 Tracker App The MeAgain app is an all-in-one GLP-1 medication tracker for iPhone and Android, designed for individual users of Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, tirzepatide, oral GLP-1s, and compounded versions. The free tier includes shot/pill tracking, food logging via photo/barcode/voice/search/quick-add, automatic protein/fiber/water monitoring, side-effect logging, weight trends, progress photos, and the GLP-1 Plotter medication-level chart; Apple Health sync is supported.
• MeAgain Premium Subscription MeAgain Premium is the paid subscription add-on for the MeAgain app that unlocks the Capy AI companion (conversational support with unlimited chat and a Capy widget), richer food/nutrition data, Journey Cards for visual progress, and enhanced progress-photo tools; offered to individual GLP-1 medication users on monthly, annual, and multi-year billing cadences.

Quantifiable outcome

• 421,000+ people track their GLP-1 journey with MeAgain
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature7 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Shotsy: Direct peer focused on GLP-1/semaglutide shot tracking. Overlaps heavily with MeAgain on dose logging, injection site tracking, and medication-level charting for Ozempic, Wegovy, Mounjaro, and Zepbound users.
• Cal AI: Direct peer (and named comparison on MeAgain's site) using AI photo-based calorie and macro tracking. Overlaps on multi-modal food logging, AI-driven nutrition estimation, and the consumer calorie-tracking category MeAgain competes in.
• Cronometer: Direct peer in detailed nutrition and macro tracking. Comparable on the protein/fiber/water tracking and detailed nutrition estimation side of MeAgain's offering.
• MacroFactor: Direct peer focused on macro tracking and adaptive coaching. Comparable on nutrition logging and weight-trend analysis features used by GLP-1 users for protein and muscle-preservation goals.
• Pep: Direct peer positioning as a GLP-1 companion app with dose reminders, side-effect tracking, and progress visualization. Targets the same Ozempic/Wegovy/Zepbound user base with comparable feature overlap.
• Lose It!: Direct peer in calorie and food tracking with barcode scanning and macro goals. Comparable on the food-logging and weight-tracking dimensions, though less specialized for GLP-1 adherence.

Broad incumbents

• Noom: Broad incumbent in behavior-change weight-loss programs with psychology-driven coaching. Comparable on weight-loss journey engagement, though a different model (coaching-led vs. self-serve tracker).
• MyFitnessPal: Broad incumbent in calorie and food tracking with a massive installed base. Represents the largest competitive threat if it deepens GLP-1-specific tracking features into its existing app.
• WW (WeightWatchers): Broad incumbent weight-loss program with points-based tracking. Competes for the same weight-management consumer and has begun integrating GLP-1 support, making it a category competitor.

Emerging players

• Found: Emerging player combining weight-management medication access with lifestyle tracking. Comparable on GLP-1 patient journey, though Found's model centers on prescribing rather than pure self-serve tracking.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php?id=61574528357744
• Instagraminstagram.com/me_again_glp1
• TikToktiktok.com/@meagain_the_glp1_company
• LinkedInlinkedin.com/company/meagainglp1

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MeAgain